Walleye Capital LLC Halozyme Therapeutics, Inc. Call Options Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $66,690 - $83,746	1,300 Added 44.83%	4,200 $240,000
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $253,327 - $351,080	-6,700 Reduced 69.79%	2,900 $151,000
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $262,704 - $327,210	7,800 Added 433.33%	9,600 $390,000
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $53,312 - $67,360	-1,600 Reduced 47.06%	1,800 $66,000
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $123,964 - $149,702	3,400 New	3,400 $129,000
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $8,012 - $11,888	-200 Reduced 50.0%	200 $11,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $15,412 - $20,712	400 New	400 $16,000
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $2,986 - $3,906	-200 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $203,680 - $237,046	-13,400 Reduced 98.53%	200 $3,000
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $200,600 - $234,736	13,600 New	13,600 $234,000

544

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.71B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.